KR20090081860A - 가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물 - Google Patents
가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물 Download PDFInfo
- Publication number
- KR20090081860A KR20090081860A KR1020080007982A KR20080007982A KR20090081860A KR 20090081860 A KR20090081860 A KR 20090081860A KR 1020080007982 A KR1020080007982 A KR 1020080007982A KR 20080007982 A KR20080007982 A KR 20080007982A KR 20090081860 A KR20090081860 A KR 20090081860A
- Authority
- KR
- South Korea
- Prior art keywords
- diabetes
- aloe vera
- pag
- vera gel
- processed aloe
- Prior art date
Links
- 235000011399 aloe vera Nutrition 0.000 title claims abstract description 86
- 235000002961 Aloe barbadensis Nutrition 0.000 title claims abstract description 81
- 244000186892 Aloe vera Species 0.000 title claims abstract description 81
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 66
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 238000000502 dialysis Methods 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 150000004676 glycans Chemical class 0.000 claims abstract description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 51
- 239000008103 glucose Substances 0.000 claims description 51
- 208000024891 symptom Diseases 0.000 claims description 18
- 206010022489 Insulin Resistance Diseases 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 208000010444 Acidosis Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000003790 Foot Ulcer Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 208000023516 stroke disease Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000018677 Skin and Connective Tissue disease Diseases 0.000 claims 2
- 208000018914 glucose metabolism disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 14
- 239000000499 gel Substances 0.000 description 81
- 241000699670 Mus sp. Species 0.000 description 59
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 40
- 239000008280 blood Substances 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 31
- 239000003925 fat Substances 0.000 description 23
- 102000004877 Insulin Human genes 0.000 description 20
- 108090001061 Insulin Proteins 0.000 description 20
- 229940125396 insulin Drugs 0.000 description 20
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 18
- 235000009200 high fat diet Nutrition 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 14
- 235000021590 normal diet Nutrition 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 13
- 230000003178 anti-diabetic effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 229960005095 pioglitazone Drugs 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 201000010063 epididymitis Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 241001116389 Aloe Species 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- 240000007474 Aloe arborescens Species 0.000 description 2
- 235000004509 Aloe arborescens Nutrition 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000012528 insulin ELISA Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- UFBGZWVLKQSSJS-DEJKXBRXSA-N (3S,3aS,5aS,5bR,7aS,11aR,11bS,13aR,13bS)-3a,5a,8,8,11a,13a-hexamethyl-3-propan-2-yl-1,2,3,4,5,5b,6,7,7a,9,10,11,11b,12,13,13b-hexadecahydrocyclopenta[a]chrysene Chemical compound CC(C)[C@@H]1CC[C@H]2[C@@]1(C)CC[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)CCC[C@]4(C)[C@H]3CC[C@]21C UFBGZWVLKQSSJS-DEJKXBRXSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
- 가공된 알로에 베라 겔(PAG)을 유효성분으로 포함하는 제2형 당뇨병, 또는 당뇨병 관련 질환 또는 증상의 예방 또는 치료용 의약 조성물.
- 제1항에 있어서, 가공된 알로에 베라 겔(PAG) 중의 다당류의 함량은 증류수에 대하여 대량 투석시(extensive dialysis), 투석망 내의 잔류 프랙션의 건조량(중량 컷-오프, 3500 달톤)에 기초하여 5% 내지 40%인 의약 조성물.
- 제1항에 있어서, 가공된 알로에 베라 겔(PAG) 중의 다당류의 함량은 증류수에 대하여 대량 투석시(extensive dialysis), 투석망 내의 잔류 프랙션의 건조량(중량 컷-오프, 3500 달톤)에 기초하여 20% 내지 30%인 의약 조성물.
- 제1항에 있어서, 가공된 알로에 베라 겔(PAG) 중의 만노즈 및 글루코즈 평균몰비가 5-40:1인 의약 조성물.
- 제1항에 있어서, 당뇨병 관련 질환 또는 증상은 고혈당증, 고인슐린혈증, 고지혈증, 인슐린 내성, 글루코즈 대사장애, 비만, 당뇨성 망막증, 황반 변성, 백내장, 당뇨성 신병증, 사구체 경화증, 당뇨성 신경질환, 발기 부전, 월경전 증후군, 혈관 재협착, 궤양성 대장염, 관상동맥질환, 고혈압, 협심증, 심근 경색, 뇌졸중, 피부 및 결합 조직 질환, 족부 궤양, 대사성 산증, 관절염, 골다공증 및 내당력 장애로 이루어진 군에서 선택되는 질환 또는 증상인 의약 조성물.
- 가공된 알로에 베라 겔(PAG)을 유효성분으로 포함하는 제2형 당뇨병 질환, 또는 당뇨병 관련 질환 또는 증상의 완화 또는 개선용 건강기능식품.
- 제6항에 있어서, 당뇨병 관련 질환 또는 증상은 고혈당증, 고인슐린혈증, 고지혈증, 인슐린 내성, 글루코즈 대사장애, 비만, 당뇨성 망막증, 황반 변성, 백내장, 당뇨성 신병증, 사구체 경화증, 당뇨성 신경질환, 발기 부전, 월경전 증후군, 혈관 재협착, 궤양성 대장염, 관상동맥질환, 고혈압, 협심증, 심근 경색, 뇌졸중, 피부 및 결합 조직 질환, 족부 궤양, 대사성 산증, 관절염, 골다공증 및 내당력 장애로 이루어진 군에서 선택되는 질환 또는 증상인 건강기능식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080007982A KR101127454B1 (ko) | 2008-01-25 | 2008-01-25 | 가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080007982A KR101127454B1 (ko) | 2008-01-25 | 2008-01-25 | 가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090081860A true KR20090081860A (ko) | 2009-07-29 |
KR101127454B1 KR101127454B1 (ko) | 2012-03-23 |
Family
ID=41293080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080007982A KR101127454B1 (ko) | 2008-01-25 | 2008-01-25 | 가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101127454B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101362003B1 (ko) * | 2011-12-23 | 2014-02-12 | 정숙연 | 뼈 치료 및 마사지용 약제의 제조방법 |
CN104689195A (zh) * | 2015-02-26 | 2015-06-10 | 邵明凤 | 一种预防心肌梗死后心室重构的中药制剂 |
KR101533191B1 (ko) * | 2014-04-18 | 2015-07-02 | 주식회사김정문알로에 | 알로에 베라 겔을 농축한 고분자분획과 달맞이꽃 종자 추출물을 포함하는 제2형 당뇨병 예방 및 치료용 의약조성물 |
JP2019126275A (ja) * | 2018-01-23 | 2019-08-01 | 裕之 木元 | 健康食品 |
KR20190105971A (ko) * | 2018-03-07 | 2019-09-18 | 주식회사 제넨셀 | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101520643B1 (ko) * | 2013-08-08 | 2015-05-15 | 주식회사김정문알로에 | 알로에 베라 겔을 농축한 제2형 당뇨병 예방 및 치료용 의약조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
KR20030087726A (ko) * | 2002-05-09 | 2003-11-15 | 주식회사 남양알로에 | 알로에 베라 겔을 포함하는 독성물질 해독용 조성물 |
-
2008
- 2008-01-25 KR KR1020080007982A patent/KR101127454B1/ko active IP Right Grant
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101362003B1 (ko) * | 2011-12-23 | 2014-02-12 | 정숙연 | 뼈 치료 및 마사지용 약제의 제조방법 |
KR101533191B1 (ko) * | 2014-04-18 | 2015-07-02 | 주식회사김정문알로에 | 알로에 베라 겔을 농축한 고분자분획과 달맞이꽃 종자 추출물을 포함하는 제2형 당뇨병 예방 및 치료용 의약조성물 |
CN104689195A (zh) * | 2015-02-26 | 2015-06-10 | 邵明凤 | 一种预防心肌梗死后心室重构的中药制剂 |
JP2019126275A (ja) * | 2018-01-23 | 2019-08-01 | 裕之 木元 | 健康食品 |
KR20190105971A (ko) * | 2018-03-07 | 2019-09-18 | 주식회사 제넨셀 | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR101127454B1 (ko) | 2012-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4353982B2 (ja) | 糖尿病処置用相乗作用組成物 | |
Said et al. | Maintaining a physiological blood glucose level with ‘glucolevel’, a combination of four anti‐diabetes plants used in the traditional Arab herbal medicine | |
US7674486B2 (en) | Synergistic composition for the treatment of diabetes mellitus | |
KR101127454B1 (ko) | 가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물 | |
WO2005000330A1 (en) | Angiogenic agents from plant extracts, gallic acid, and derivatives | |
BRPI0822169A2 (pt) | uma composição e um processo da mesma | |
US5980902A (en) | Compositions for treating and preventing diabetes, impaired glucose tolerance and related symptoms, and methods for preparing and using such compositions | |
US11065292B2 (en) | Feijoa fruit extract | |
KR20130020623A (ko) | 유홍초 추출물을 함유하는 당뇨합병증 예방 또는 치료용 조성물 | |
Bhavapriya et al. | Biochemical studies on hypoglycemic effect of Aavirai Kudineer: a herbal formulation in alloxan diabetic rats | |
KR20170108222A (ko) | 상지 열수추출물과 oxyresveratrol을 유효성분으로 함유하는 항당뇨 기능성 조성물 및 그 제조방법 | |
KR101095467B1 (ko) | 액티브알로에 디엠(ACTIValo e DM), 또는 액티브알로에 디엠(ACTIValo e DM) 및 크롬(Cr)의 혼합물을 포함하는 제2형 당뇨병 예방 또는 치료용 의약 조성물 | |
KR100542809B1 (ko) | 혈당 강하용 생약 조성물, 이의 제조방법 및 이를포함하는 약학제재 | |
Taiwo et al. | Glycaemic activity of Ficus exasperata in fructose-induced glucose intolerance in rats | |
KR20120016131A (ko) | 경구 섭취 형태의 양이온성 하이드록시에틸셀룰로오스의 용도,및 대사 장애의 예방 및 치료 | |
KR100832321B1 (ko) | 고지혈증 개선을 위한 홍삼 산성다당체 함유 건강기능식품 | |
JP5019708B2 (ja) | 糖尿病の治療および予防用組成物 | |
KR101520643B1 (ko) | 알로에 베라 겔을 농축한 제2형 당뇨병 예방 및 치료용 의약조성물 | |
Sindhu et al. | Trigonella foenum-graecum L.: Therapeutic and Pharmacological Potentials—Special Emphasis on Efficacy against Inflammation and Pain | |
Zim | Effect of okra (Abelmoschus esculentus) mucilage on glucose level and lipid profile of alloxan-induced diabetic mice | |
CN107951872B (zh) | 一种治疗糖尿病的口服药物组合物 | |
KR100473529B1 (ko) | 순기산 생약 복합제 추출물을 유효성분으로 함유하는당뇨병 예방 및 치료용 조성물 | |
Sari et al. | THE ANTIDIABETIC EFFECT OF KONJAC GLUCOMANNAN ON GLUCOSE LEVEL DIABETIC RATS | |
US20070031521A1 (en) | Synergistic composition for the treatment of diabetes mellitus | |
KR20200144896A (ko) | 금어초 추출물을 유효성분으로 함유하는 혈당 강하용 건강기능식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150306 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151217 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170309 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190214 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200309 Year of fee payment: 9 |